Risperidone and haloperidol in delirium

A phase III randomised, double-blind placebo controlled study to compare the effectiveness of oral Risperidone and oral Haloperidol in the management of delirium

DOI	10.58084/c81x-td25
Type of DOI	Dataset
Publisher	Cancer Symptom Trials (CST)
Creator(s)	Meera Agar, Liverpool Hospital
Date made available	2023
Description of dataset	Dataset includes: Two hundred forty-seven participants were included in intention-to-treat analysis (82 receiving risperidone, 81 receiving haloperidol, and 84 receiving placebo. Treatment period over 72 hours
Funding	Australian Government
Subject (ANZSRC category)	Clinical sciences (pain)
ANZCTR reference	ACTRN12607000501448
Main trial page	PaCCSC clinical trials
Publications	Efficacy of Oral Risperidone, Haloperidol, or Placebo for Symptoms of Delirium Among Patients in Palliative Care: A Randomized Clinical Trial
Dataset access	Access can be requested via the Health Data Australia catalogue. Search for the ACTRN number in the catalogue to find datasets associated with these trials or email enquiries to hesanda@uts.edu.au.

Acknowledgement of Country

UTS acknowledges the Gadigal people of the Eora Nation, the Boorooberongal people of the Dharug Nation, the Bidiagal people and the Gamaygal people, upon whose ancestral lands our university stands. We would also like to pay respect to the Elders both past and present, acknowledging them as the traditional custodians of knowledge for these lands.